Aba Chemicals Corporation(300261) issued a supplementary announcement to a2w Pharma Ltd, a subsidiary of the company in Malta. The CBD (cannabinoid) product production workshop of has not been put into operation and has not sold any CBD products, which will not have a significant impact on the company’s performance. Affected by the epidemic in Europe, the company expects that the CBD products of a2w Pharma Ltd. will be officially put into operation in the first quarter of 2023. The main products are 700 kg of cannabinoid (CBD) and tetrahydrocannabinol (THC) extracts and 400000 bottles of 30 ml preparation products per year. The company’s CBD product production workshop is still under construction, and the project product production may be different from the original plan due to the influence of objective factors. If the supply and demand situation changes in the future, it will have an adverse impact on the project. In addition, carbonic anhydride is the primary intermediate of antiviral drugs. It was originally the starting material of bosepivir developed and produced by the company in the early stage. It is estimated that the sales revenue of this product accounts for about 0.5% – 2% of the company’s total operating revenue this year, which accounts for a relatively small proportion and will not have a significant impact on the company’s performance.
(Financial Associated Press)
